Tüdőrák: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• EGFR 300
• PD-L1 162
• PD-1 156
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

18+ intézményből 18, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spanyolország· EU contribution 262 393 EUR· until 2030. febr.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Svájc· EU contribution 1 874 590 EUR· until 2032. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, Franciaország· EU contribution 242 261 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution 216 240 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 426 534 EUR· until 2030. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting selenocysteine metabolism as a novel vulnerability in refractory non-small-cell lung cancer (SelenoResist)

  Universitat Wien· Wien, Ausztria· EU contribution 214 345 EUR· until 2028. nov.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spanyolország· EU contribution 150 000 EUR· until 2028. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Specific delivery of active biomolecules to treat lung cancer (SafeDelivery)

  Fundacio Centre de Regulacio Genomica· Barcelona, Spanyolország· EU contribution 3 323 826 EUR· until 2031. okt.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Delivering a '1-2 punch' to RAS-driven cancers (RAS-PUNCH)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 236 340 EUR· until 2028. okt.

10 of 66 running projects, newest first. Listed amounts together: 224,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Frissítve: 2026. okt. 26.

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

  NCT04982224· Regeneron Pharmaceuticals· Frissítve: 2025. nov. 3.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

  NCT04926831· Novartis Pharmaceuticals· Frissítve: 2025. okt. 16.

  “The study was terminated early due to recruitment challenges.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

  NCT06093503· AbbVie· Frissítve: 2024. jún. 26.

  “Strategic considerations”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

  NCT05567055· Timothy Burns, MD, PHD· Frissítve: 2024. jún. 17.

  “Slow enrollment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

  NCT05435846· Collin Blakely· Frissítve: 2024. jún. 11.

  “slow accrual”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

  NCT04460729· Novartis Pharmaceuticals· Frissítve: 2020. dec. 3.

  “company decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Premedication to Reduce Amivantamab Associated Infusion Related Reactions

  NCT05663866· Janssen Research & Development, LLC· Forrás

• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT04928846· AbbVie· Forrás

• A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)

  NCT07613424· AstraZeneca· Forrás

• Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

  NCT05110196· Novartis Pharmaceuticals· Forrás

• A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT06568939· AbbVie· Forrás

• Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

  NCT07863024· Regeneron Pharmaceuticals· Forrás

• A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT07821684· AbbVie· Forrás

• A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

  NCT06147037· AstraZeneca· Forrás

• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

  NCT04077099· Regeneron Pharmaceuticals· Forrás

• Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

  NCT03040973· Novartis Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 617
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• Integrative whole-exome sequencing and functional validation identify drivers of lung cancer metastasis seeding and colonization in the brain.

  Cell Cycle, 2026. okt.

• Pleural Mesothelioma With Unusual Squamous Differentiation: A Clinicopathological Case Report With Molecular Insights From Whole-Exome Sequencing.

  Pathol Int, 2026. okt.

• Phylogenetic and phylodynamic approaches to understanding the evolution of non-small cell lung cancer using single-cell sequencing.

  Oncogene, 2026. szept.

• Integrated genomic and immunophenotypic profiling reveals monoclonal origin, smoking-driven evolution and heterogeneous microenvironment in pulmonary adenosquamous carcinoma.

  Front Immunol, 2026. jún.

• Exploratory plasma ctDNA genomic biomarkers identified by whole-exome sequencing and a novel bioinformatics pipeline in advanced driver-negative NSCLC.

  Sci Rep, 2026. máj.

• Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy.

  Cancer Immunol Immunother, 2026. máj.

• Genetic analysis of primary lung interdigitating dendritic cell sarcomas.

  J Pathol, 2026. máj.

• Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small-cell lung cancer.

  Cell Rep Med, 2026. ápr.

• Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors.

  J Med Econ, 2026. márc.

• Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab.

  Int J Mol Sci, 2026. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.